# A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

> **NCT01673737** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 75 (actual)

## Conditions studied

- Neoplasm Malignant

## Interventions

- **DRUG:** SAR260301
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01673737
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2015-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01673737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01673737, "A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01673737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*